Research programme: serotonin 6 receptor antagonists - Suven Life Sciences
Alternative Names: 5HT6 compounds; SUVN-501; SUVN-504; SUVN-507; SUVN-512; SUVN-623; SUVN-901; SUVN-976Latest Information Update: 28 Jan 2022
Price :
$50 *
At a glance
- Originator Suven Life Sciences
- Class Antidementias; Antiparkinsonians; Antipsychotics; Carbazoles; Indoles; Neuroprotectants; Obesity therapies; Small molecules; Sulfonamides; Tryptamines
- Mechanism of Action Serotonin 6 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Alzheimer's disease; Cognition disorders; Huntington's disease; Obesity; Parkinson's disease; Schizophrenia
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for preclinical development in Huntington's-disease in India (PO)
- 28 Nov 2019 No recent reports of development identified for preclinical development in Alzheimer's-disease in India (PO)
- 28 Nov 2019 No recent reports of development identified for preclinical development in Cognition-disorders in India (PO)